secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cibus, Inc. (CBUS)
CIK:        0001705843
Form:       8-K
Filed at:   2026-08-13T20:14:58+00:00
Accession:  0001628280-26-056731
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cibus Q2 net loss $22.1M, cash $20.4M, EU gene-editing rule favorable, Interoc expands to 5 Rice traits
--------------------------------------------------------------------------------

- Net loss $22.1M vs $26.6M YoY; EPS -$0.29 vs -$0.61.
- Cash $20.4M; expects to fund into early Q1 2027; quarterly net cash usage down 19% QoQ, 31% YoY.
- EU approved gene-edited crops as conventional (June 2026); supports Rice and other programs.
- Interoc amended LOI to expand from 2 to 5 Rice traits; potential 2028 launch.
- Craig Wichner appointed CEO effective June 8, 2026; Peter Beetham remains President/COO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1705843/000162828026056731/0001628280-26-056731-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1705843/000162828026056731/cbus-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-056731

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer